Heterobifunctional compounds (HBCs) that recruit E3 ligases to induce targeted protein degradation have emerged as promising therapeutic agents for cancer. Current HBC screening strategies prioritize biochemical degradation assays over functional anti-cancer activity assays. This approach may miss compounds with modest target protein degradation yet significant biological activity via alternative mechanisms. To address this, we developed an integrated chemical-genetic screening platform using is